Spanning topics across R&D, clinical trials, and commercial launch, our podcast series continues as two clinical supplies ...

England has launched a world-first gonorrhoea vaccination programme that will potentially help avert up to 100,000 cases of the disease and save millions of NHS funding.

APAC-based biotech companies in Singapore, South Korea and Japan may offer investors the stability and innovation they are searching for.

The Gates Foundation has announced an investment of $2.5bn to 2030, dedicated to expediting R&D with a focus on improving women's health.

For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation between the US and the EU.

The Saudi Food and Drug Authority (SFDA) has approved Agios' Pyrukynd (mitapivat) for adults with alpha or beta-thalassemia.

Analysis by GlobalData characterises an uncertain pharma landscape, though big pharma CEOs allay investor concern.

Sandoz will acquire Just – Evotec Biologics’ biosimilar development and manufacturing plant in Toulouse for $300m.

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

Arrowhead's subsidiary Visirna has entered an agreement with Sanofi for plozasiran, a potential treatment for hypertriglyceridemia.

Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide drug discovery.

Europe’s cannabis pharmaceutical sector is shifting as scientific rigour, regulatory clarity and cautious capital define its next chapter.